ROG:VX: APHINITY headline positive but await full data
Awaiting full data: Roche announced that APHINITY met its primary endpoint , but as expected details are to be published at an upcoming...
top of page
Recent Research
Feb 6, 2017
ROG.VX: APHINITY too close for comfort
We present the third update of our APHINITY analysis, originally published two years ago and find the risks of early stage Perjeta...
Jan 20, 2017
BMY.US: No Accelerated pathway does not imply registrational failure
Bristol's announcement that it is not pursuing an accelerated FDA approval pathway for Yervoy and Opdivo in first line lung cancer was...
Jan 17, 2017
AZN.LN: MYSTICal Endpoints unravelled
Endpoints claified: There have recently been some uncertainties surrounding the exact endpoint and timings of the upcoming MYSTIC IO/IO...
Dec 3, 2016
AZN.LN: Mystical Endpoints
What's the endpoint?: There have recently been some uncertainties surrounding the exact endpoint and timings of the upcoming MYSTIC combo...
Oct 27, 2016
AZN.LN: Head and neck hold may explain BMYs hesitance with combo
Head and neck specific? The FDA placed a partial clinical trial hold on recruiting new patients to AstraZeneca’s anti PD-L1 (durvalumab)...
Oct 17, 2016
PD1 Combos at ESMO good for AZN and BMY not for MRK and ROG
Chemo combos continue to look equivocal, while IO combos remain durable as MYSTIC’s shadow clears New ESMO lung cancer data bodes well...
Oct 13, 2016
Unravelling the MYSTICal
Astra's underappreciated oncology pipeline stalking the market We initiate on AstraZeneca with an overweight rating and a Target Price of...
Sep 30, 2016
ESMO 2016: all anti PD1/PDL1 checkpoint inhibitors are not the same
Pressure on anti PD-L1s: ESMO 2016 increases the body of evidence that anti PD-L1s from Roche, Astra and PFE/MRCG may fall short of PD-1s...
Aug 8, 2016
Consensus PD1 hopes under threat
PD1 market continues to shrink, but Bristol’s failure not good news for rivals BMY announced Friday that its pivotal phase III study of...
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page